Who we are
D-Sight is a spin-off company from Vall d’Hebron Institute of Research (VHIR) lead by an experienced and committed team dedicated to the discovery and development of new innovative treatments for neurodegenerative diseases of the retina.
WHO WE ARE
D-Sight is a spin-off company from Vall d’Hebron Institute of Research (VHIR) lead by an experienced and committed team dedicated to the discovery and development of new innovative treatments for neurodegenerative diseases of the retina.
Improving the quality of life of diabetic patients
We have developed a first-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.
D-Sight addresses a wide-spread unmet medical need with a cost-effective, non-invasive and safe treatment, which also prevents side-effects and limitations associated to current standard-of-care therapies.
An early treatment for the leading cause of
preventable blindness in working-age population
643M
ADULTS SUFFERING DIABETES WORLDWIDE
BY 2030
60%
TYPE 2 DIABETIC PATIENTS (AND NEARLY ALL TYPE 1) DEVELOPT DIABETIC RETINOPATHY
185M
ADULTS SUFFERING DIABETIC RETINOPATHY IN WORKING-AGE WORLDWIDE
Team members
D-Sight is founded and lead by world leaders in diabetic retinopathy, diabetes and other neurodegenerative diseases linked to the retina.
FOUNDERS
CEO
Carla Maté Goldar
CMO
Rafael Simó Canonge
CSO
Cristina Hernández Pascual
SUPPORTED BY
-NEGATIU.png)
